

Comparative Bioavailability to Humans of Ascorbic Acid Alone or in a Citrus Extract

Joe A. Vinson, PhD
Pratima Bose, PhD

Reprinted from the AMERICAN JOURNAL OF CLINICAL NUTRITION
Vol. 48, No. 3
September 1988

These studies may not conform to peer review standards. Therefore, the results are not conclusive.

Comparative bioavailability to humans of ascorbic acid alone or in a citrus extract 1,2

Joe A Vinson, PhD, and Pratima Bose, PhD

ABSTRACT This study was performed to determine whether synthetic ascorbic acid (AA) alone or in a natural citrus extract containing bioflavonoids, proteins, and carbohydrates was more bioavailable to human subjects. The effect of a single 500-mg ascorbate dose of the two forms and a placebo citrus extract on plasma ascorbate was examined in eight fasting subjects. A comparison of the areas under the plasma concentration-time curves showed that the citrus extract was 35% more absorbed than AA ($p < 0.001$) and was more slowly absorbed than AA ($p < 0.001$). In six ascorbate-saturated male subjects the ascorbate in the citrus extract produced a greater ascorbate excretion than AA alone in 24-h post-dose urine ($p < 0.05$). Citrus extract ascorbate was less excreted than AA ($p < 0.05$) in 12 nonsaturated subjects. Ascorbate in the citrus extract was found to be more bioavailable than AA alone in human subjects.

Am J

Clin Nutr 1988;48:601-4.

KEY WORDS Ascorbic acid, citrus extract, bioflavonoids, bioavailability, plasma ascorbate, urinary ascorbate

Introduction

There is now considerable general interest in vitamin C (ascorbic acid) supplementation because of recent popular books on the treatment of the common cold and cancer by synthetic ascorbic acid (abbreviated here as AA). Also, certain populations such as smokers and elderly people are known to have low tissue levels of ascorbate (1,2) and might benefit from supplementation. Although natural and synthetic ascorbic acids are chemically identical, citrus fruits contain bioflavonoids such as naringin and hesperidin as well as carbohydrates and proteins that might affect the bioavailability of the ascorbate. However, individuals who drink frozen or reconstituted fruit juices are ingesting < 4 mg of total bioflavonoids/L of fruit juice (3), which are removed in processing due to their bitter taste.

The view that bioflavonoids might act as compounds that reduce the need for ascorbic acid and thus affect its tissue concentration was first postulated by a French group > 35 y ago (4). They found that the amount of ascorbate in the organs of guinea pigs was increased by the addition of bioflavonoids to the diet. Our group determined that a citrus extract containing ascorbic acid was more bioavailable to guinea pigs than AA alone (5). The effect of bioflavonoids on tissue ascorbate was the subject of an extensive review (6).

Human studies, on the other hand, have been equivocal. A Canadian group recently found that the bioavailability of pure AA was slightly superior to ascorbate in

orange juice (7). A study using interluminal perfusion of human small intestine showed no difference between ascorbate in reconstituted orange juice and AA (8). The objective of the present study was to determine the relative bioavailability of a citrus extract to that of AA alone in humans.

Subjects and methods

Test solutions

The materials compared in this study were synthetic L-AA from Fisher Chemical Company (Pittsburgh, PA) and reagent-grade vitamin C in citrus extract (CE), Citrus Fruit Medial, manufactured by Grow Company (Hackensack, NJ). The placebo CE was a light brown water-soluble powder containing 0.2% AA, 19.5% citrus bioflavonoids (19.0% naringin, 0.34% naringenin, and 0.17% hesperidin) and a minimum of 30% carbohydrates and 15% protein. The CE was identical to the placebo CE except that AA was added to a final concentration of 25.1 g/100 g as measured by a high-pressure liquid chromatography (HPLC) procedure after protein precipitation by metaphosphoric acid (9). The bioflavonoids were identified and

¹ From the Department of Chemistry, University of Scranton, Scranton, PA 18510.

² Address reprint requests to JA Vinson, Associate Professor of Chemistry, Department of Chemistry, University of Scranton, Scranton, PA 18510. Received October 6, 1986.

Accepted for publication October 13, 1987.

Am J Clin Nutr 1988;48:601-4. Printed in USA. © 1988 American Society for Clinical Nutrition

h01

quantified by HPLC (10) and were the typical flavanones of citrus fruit.

Subjects and sampling

This study was approved by the Human Subjects Committee of the University of Scranton. All subjects gave their written informed consent before participation. Eight healthy, non-smoking individuals (five males and three females) volunteered for the plasma study. The subjects ranged in age from 18-41 y with an average age of 22.6 y. None of the subjects was taking vitamin supplements and none consumed foods high in ascorbic acid on the day of the study. Each subject reported between 0800 and 0830 after an overnight fast for a base-line blood drawing by finger-prick sampling using an Autoletc11 device (Owen Mumford Ltd, Oxford, UK). This technique was shown to give a sample ascorbate concentration equivalent to the more common venipuncture method (11) at much less risk and discomfort to the subject. The blood was collected in EDT A tubes and the plasma was separated immediately after sampling. In a random crossover experimental design, each subject drank either 500 mg AA, 2 g placebo CE, or 2 g CE dissolved in 50 mL of a solution of 278 mmol glucose/L. The placebo CE provided 4 mg ascorbate and the CE, 502 mg. Finger-prick samples were taken 1, 2, 3, 4, 6, and 8 h after dosing. Subjects were not allowed to eat until after the last sampling but were allowed to drink water as desired. A 0.1-mL aliquot of blood plasma was immediately mixed with an equal volume of 1.56 mol metaphosphoric acid/L and frozen at -20 .C. The next day the samples were analyzed by a fluorometric method (12) that measures unoxidized ascorbate. Bioflavonoids did not give a fluorescence with this procedure and therefore did not interfere. At weekly intervals the subjects ingested the other formulations and the sampling procedure was repeated.

Six males aged 21-41 y with an average age of 26.8 y volunteered for the first urine study. The subjects were saturated with AA in a protocol similar to that of Robinson (13). After 2 wk of consuming 1 g AA to saturate the body stores, the subjects avoided ascorbic acid for 2 d before the experimental day. During the second day of this 2-d period, a 24-h urine collection was made for use as a blank. After fasting overnight the subjects ingested in the morning 500 mg of ascorbate in one of the two forms, AA or CE (dissolved in 50 mL of a solution of 278 mmol glucose/L), in a random crossover experimental design. The subjects were then allowed to eat lunch and dinner while still avoiding foods high in ascorbic acid. A 24-h urine collection was made. The following day the subjects resumed taking 1 g AA for 5 d and then stopped for 2 d before ingesting the other form. Twenty-four-hour blank and postdose urine was collected as before. Urine was stored in plastic specimen bottles over 50 mL of 3.12 mol metaphosphoric acid/L, kept refrigerated between collections, and frozen at -20 .C until analysis within 1 wk. The 24-h volume was recorded and an aliquot was taken for fluorimetric analysis of total ascorbate after reduction of dehydroascorbic acid with mercaptoethanol.

Twelve subjects (six males and six females) volunteered for the second urine study. They ranged in age from 18-41 y with an average age of 22.6 y. A blank 24-h urine collection was made the day before dosing. After an overnight fast subjects consumed either AA, placebo CE, or CE as in the plasma study. Twenty-four-hour urine was collected as described previously. One week later another 24-h urine blank was collected. The other forms were given and the procedure was repeated. The subjects avoided foods high in ascorbic acid in their diet 1 wk before the experiment and during the week of the experiment.

TABLE I
Areas under the plasma ascorbate time-concentration curves after oral administration of 500 mg ascorbate in the form of synthetic ascorbic acid (AA) alone or in a citrus extract (arbitrary units)

Subject

2 3 4 5 6 7 8
x:tSD

Plasma ascorbate area	
AA	Citrus extract

Age

Sex AA Citrus extract

18 18 19 41 21 22 21 18

F F F M M M M M

571 748 389 672 470 565 656 651
590:t 117

.Significantly different by a paired *t* test ($p < 0.001$).

Data analysis

Areas under the plasma ascorbate concentration-time curves were measured for each individual by manual planimetry with a reproducibility of 2.5%. The points for determining the time for maximal ascorbate concentration were plotted by a cubic spline curve-fitting program on an IBM PC (model XT) computer (Armonk, NY).

Statistical comparisons of the results were made by a paired or two-sample Student's *t* test.

Results

The initial mean \pm SD fasting plasma ascorbate was 35.2 \pm 13.7 μ Mol/L (range, 14.8-69.8 μ Mol/L). These are typical values of a normal population (14). There was no significant difference between male and female subjects, with levels of 35.1 \pm 14.2 and 35.2 \pm 11.1 μ Mol/L, respectively. The extent of absorption of ascorbate was determined by comparing the areas under the plasma ascorbate concentration-time curves after administration of each formulation. Because absorption of AA is dose-dependent (15), comparison of AA and CE was made at the same dose of ascorbic acid. The areas were measured for each subject and the data are shown in Table 1. There was no significant difference between males and females for either AA or CE; therefore, the results were combined. All subjects showed a greater area under the curve for CE than for AA. The ascorbate in the CE was found to be significantly more absorbed than the AA ($p < 0.001$).

The average plasma ascorbate curves for the three formulations are shown in Figure 1. The maximal ascorbate concentrations were 197 \pm 20.2 μ Mol/L for AA, 209 \pm 32.9 μ Mol/L for CE, and 56.8 \pm 11.9 μ Mol/L for placebo CE. The time for maximal plasma ascorbate was 2.9 \pm 0.3 h for AA and 4.1 \pm 0.5 h for CE ($p < 0.001$). A statistical evaluation of the AA and CE curves in Figure 1 indicates that there was no significant difference be-

COMPARATIVE ASCORBATE BIOAVAILABILITY




TABLE 3
Net 24-h urinary excretion of ascorbate after oral administration of a placebo citrus extract or 500 mg synthetic ascorbic acid (AA) alone or in a citrus extract (mg) *

	Urinary ascorbate			
Males (n = 6)	181 ± 89	-2.3 ± 11.4	72 ± 35	<0.05
Females (n = 6)	93 ± 32	-26.9 ± 38.7	71 ± 29	NS
All subjects	135 ± 79	-10.5 ± 23.2	72 ± 31	<0.05

* $\bar{x} \pm$ SD.

† Significance of difference between AA and citrus extract by a paired *t* test.

AA

Placebo
citrus extract

603

Citrus extract

pt

TIME (hours)

FIG 1. Plasma time-concentration curves for eight fasting subjects ingesting 500 mg of ascorbate as synthetic ascorbic acid (AA) alone or in 2 g of a citrus extract, or 2 g placebo citrus extract, or 2 g placebo citrus extract (*x*:*t* SD). (To convert mg/dL to μmol/L, multiply by 56.78.)

tween the two dose forms except at 4 h after ingestion when the CE produced a 68% greater plasma ascorbate than AA (*p* < 0.005). The placebo CE produced a small but significant increase in plasma ascorbate after 3 h compared with the 0-h value (*p* < 0.05).

The results of the first urine excretion study after a previous saturation of body stores with ascorbate are shown in Table 2. All six subjects showed a greater excretion of ascorbate after ingestion of CE compared with AA (*p* < 0.05).

Results of the second urine study of subjects who were not saturated with ascorbate are displayed in Table 3. The placebo CE produced no net excretion of ascorbate. There was no significant difference between the male and female excretion data for AA or CE although males tended to excrete more ascorbate after AA ingestion than did females. Five of the six males and four of the six females excreted more ascorbate after ingestion of AA than

TABLE 2
Net 24-h urinary excretion of ascorbate after oral administration of 500 mg synthetic ascorbic acid (AA) alone or in a citrus extract to AA-saturated subjects (mg)

Urinary ascorbate

Subject

1 8.0 2 73.4 3 49.6 4 102.1 5 36.8 6 108.4

x:*t* SO 63:38.9

.Significantly different by a paired *t* test (*D* < 0.05).

AA

Citrus extract

26.4 157.7 189.9 172.1 43.2

262.1

141.9:1: 90.5*

after ingestion of CE and the difference between the two forms was significant (*p* < 0.05).

Discussion

A comparison of the areas under the plasma ascorbate concentration-time curves (Table 1) allows the determination of the relative bioavailability of the two forms. The ascorbate in the CE was found to be 35% more bioavailable than AA alone (*p* < 0.001). This result is similar to the 48% greater bioavailability of CE found in our guinea pig study (8). These findings seem to contradict an earlier human study by Pelletier and Keim (6) who found that AA plus the bioflavonoid rutin produced a slightly lower serum ascorbate increase than did AA alone. However, that study measured ascorbate 2 h post-dose, at which time our data showed no significant difference between AA alone and the CE that contained bioflavonoids (Fig 1). The area under the placebo CE curve was 9.4% of that under the CE curve. This percentage is more than would be expected from the ascorbate in the placebo CE, which is only 0.8% of the CE ascorbate. This result from a human study corroborates previous data reviewed by Hughes and Wilson (5) that showed elevated tissue ascorbate in guinea pigs after administration of bioflavonoids.

As seen in Figure 1, the CE produced a peak plasma ascorbate concentration at a longer time interval after ingestion than did AA. This was not a dosage-form difference because both CE and AA were given in solution. The result indicates that the CE was more slowly absorbed than the AA. The time for

maximum concentration for AA was 2-9 h which is nearly identical to the 2.8 h found by Zeitler et al (15). The time for the CE was 4.1 h, similar to the 4-5 h found by other workers after ingestion of timed-release formulations of AA (13, 16).

To use urinary-excretion data to compare the absorption of the two forms of ascorbic acid, it is necessary to saturate the body stores because the retention of ascorbate in the body is influenced by the nutritional status of the individual (13). The fact that the subjects were saturated is corroborated by the significantly greater blank

604

VINSON AND BOSE

24-h urinary ascorbate in the saturated group than in the unsaturated group in the second urine study (158.0 ± 59.5 mg and 77.5 ± 35.2 mg, respectively [$p < 0.05$ by a two-sample t test]). The excretion from the saturated group is similar to that reported by Jones (16), 237 ± 25.4 mg. The data on presaturated individuals in Table 2 confirm the plasma results that indicated that the CE was absorbed more than the AA alone. The urine results are similar to a previous study (6) which showed that AA plus rutin or fresh orange juice alone produced a greater ascorbate excretion than AA alone in presaturated subjects. Another report that confirmed these results (16) showed that black currant juice, high in bioflavonoids, produced a greater urinary excretion of ascorbate than did AA alone.

The second urine study (using nonsaturated subjects) produced different results from the first study. The results in Table 3 demonstrate that the CE produces significantly less ascorbate excretion than AA alone in nonsaturated subjects. In light of the plasma study and the first urine study, which showed increased absorption for the CE compared with AA alone, the second urine study results may be interpreted to indicate that the ascorbate in the CE is sequestered to a greater extent than AA alone in the tissues of nonsaturated subjects.

The finding that the ascorbate in CE is more bioavailable and more slowly absorbed than AA alone, ie, that it acts as a timed-release formulation, is advantageous for supplementation. The water-soluble CE does not suffer from the disadvantages of previous timed-release forms which were found to be less bioavailable than conventional forms of AA (17). Although the mechanism of the greater bioavailability of the ascorbate in CE is not known, previous studies with bioflavonoids produced two possible mechanisms: enhanced absorption and stabilization of ascorbate (5).

In conclusion, the ascorbate in the CE was found to be more slowly absorbed and more bioavailable than AA alone and is thus the preferred form of ascorbate for supplementation. II

We gratefully acknowledge the assistance of O Pelletier in the preparation of this manuscript. The citrus extract was kindly supplied by R Koetzner of Grow Comoanv. Inc. Hackensack. NJ 07601.

References

1. Pelletier O. Vitamin C status of smokers and non-smokers. *Am J Clin Nutr* 1970;23:520-4.
2. Burr ML, Elwood PC, Hole DJ, Hurley RJ, Hughes RE. Plasma and leucocyte ascorbic acid levels in the elderly. *Am J Clin Nutr* 1974;27:144-51.
3. Veldhuis MK, Swift U, Scott WC. Fully-methoxylated flavones in Florida orange juices. *J Agric Food Chem* 1970; 18:590-2.
4. Cotereau H, Gabe M, Gero E, Parrot JL. Influence of vitamin C upon the amount of ascorbic acid in the organs of the guinea pigs. *Nature* 1948; 161:557-8.
5. Hughes RE, Wilson HK. Flavonoids: some physiological and nutritional considerations. In: Ellis GP, West GB, eds. *Progress in medicinal chemistry*. Vol 14. Elsevier/North Holland: Amsterdam, 1977:285-300.
6. Pelletier O, Keith MO. Bioavailability of synthetic and natural ascorbic acid. *J Am Diet Assoc* 1974;64:271-5.
7. Nelson EW, Streiff RR, Cerda JJ. Comparative bioavailability of folate and vitamin C from a synthetic and a natural source. *Am J Clin Nutr* 1975;28:1014-9.
8. Vinson JA, Bose P. Comparative bioavailability of synthetic and natural vitamin C in guinea pigs. *Nutr Rep Int* 1983;27: 875-9.
9. Ziegler SJ, Meier B, Sticher O. Fast and selective assay of ascorbic acid in rose hips by RP-HPLC coupled with electrochemical and/or spectrophotometric detection. *Planta Med* 1986;5: 383-7.
10. Park GL, Avery SM, Byers JL, Nelson DB. Identification of bioflavonoids from citrus. *Food Technol* 1983;98-105.
11. Bradley DW, Maynard JE, Emergy G. Comparison of ascorbic acid concentrations in whole blood obtained by venipuncture or fingerprick. *Am J Clin Chem* 1972; 18:968-70.
12. Hubmann B, Monnier D, Roth M. Rapid and accurate determination of ascorbic acid in blood plasma. *Clin Chim Acta* 1969;25: 161-7.
13. Young S, Mayersohn M, Robinson JR. Ascorbic acid absorption in humans: a comparison among several dosage forms. *J Pharm Sci* 1982;71:282-5.
14. Anonymous. *Nutrition Canada Interpretive Standards*. National survey. Ottawa: Ottawa Information Canada, 1973.
15. Zeitler G, Seidel G, Siegers CP, Iven H. Pharmacokinetics of ascorbic acid in man. *Eur J Clin Pharmacol* 1976; 10:273-82.
16. Jones E, Hughes RE. The influence of bioflavonoids on the absorption of vitamin C. *IRCS Med Sci* 1984; 12:320.
17. Leopold G, Breur J, Loebich F. Different formulations of vitamin C and absorption in man. *IRCSJ Med Sci* 1975;3:74.